Dicerna Pharmaceuticals (DRNA) PT Raised to $18 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St hits two-week lows as rising bond yields, Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Dicerna Pharmaceuticals (DRNA) PT Raised to $14 at H.C. Wainwright
May 16, 2018 1:30 AM EDTH.C. Wainwright raised its price target on Dicerna Pharmaceuticals (NASDAQ: DRNA) to $14.00 (from $12.00) while maintaining a Neutral rating.
... MoreDicerna Pharma (DRNA) Tops Q1 EPS by 8c
May 14, 2018 4:11 PM EDTDicerna Pharma (NASDAQ: DRNA) reported Q1 EPS of ($0.30), $0.08 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $1.87 million.
For earnings history and earnings-related data on Dicerna Pharma (DRNA) click here.
... More